华东医药：子公司创新药马来酸美凡厄替尼片获批准上市

Core Viewpoint - Huadong Medicine's subsidiary has received approval for a new innovative drug, marking a significant advancement in treatment options for specific lung cancer patients [1] Company Summary - Huadong Medicine's wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has developed a Class 1 innovative drug, Mevanertinib tablets (brand name: Mairuidong) [1] - The drug has been approved by the National Medical Products Administration for use in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have the EGFR exon 21 (L858R) substitution mutation [1]